{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=6", "query": { "condition": "Breast Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 7073, "total_pages": 708, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T09:45:20.361Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02311933", "title": "Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Breast Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Endoxifen Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Tamoxifen Citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 81, "start_date": "2015-05-28", "completion_date": "2027-02-02", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 559, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 356 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02311933" }, { "nct_id": "NCT05754749", "title": "Comparison of CE-DBT and MRI in Patients With Known Breast Lesions", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Iohexol 350 Mg/mL Injectable Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2023-03-13", "completion_date": "2026-05-20", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05754749" }, { "nct_id": "NCT03893955", "title": "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Advanced Solid Tumors", "Triple-Negative Breast Cancer (TNBC)", "Non-small-cell-lung-cancer (NSCLC)", "Metastatic Solid Tumors" ], "interventions": [ { "name": "ABBV-927", "type": "DRUG" }, { "name": "ABBV-368", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2019-05-21", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 13, "location_summary": "Springdale, Arkansas • Santa Rosa, California • New Haven, Connecticut + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Santa Rosa", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893955" }, { "nct_id": "NCT06625515", "title": "First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Breast Cancer Recurrent", "Colorectal Cancer Metastatic", "Colon Cancer", "Rectal Adenocarcinoma", "Endometrial Cancer" ], "interventions": [ { "name": "ATX-559", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accent Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2024-10-11", "completion_date": "2026-01-09", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 5, "location_summary": "Aurora, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625515" }, { "nct_id": "NCT02795104", "title": "Rural Interventions for Screening Effectiveness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast, Cervical or Colorectal Cancer Screening Needed" ], "interventions": [ { "name": "Educational Intervention via brochure", "type": "BEHAVIORAL" }, { "name": "Educational Intervention via DVD", "type": "BEHAVIORAL" }, { "name": "Educational Intervention-DVD & Telephone Based Navigation", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "74 Years", "sex": "FEMALE", "summary": "50 Years to 74 Years · Female only" }, "enrollment_count": 985, "start_date": "2016-11", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2023-10-02", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 2, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02795104" }, { "nct_id": "NCT01300533", "title": "A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Cancer", "Solid Tumors" ], "interventions": [ { "name": "BIND-014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BIND Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-01", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Detriot", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01300533" }, { "nct_id": "NCT03330847", "title": "To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Triple Negative Breast Cancer" ], "interventions": [ { "name": "Olaparib Continuous (28-Day cycle) 300 mg BD.", "type": "DRUG" }, { "name": "Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).", "type": "DRUG" }, { "name": "Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 273, "start_date": "2018-03-07", "completion_date": "2026-10-09", "has_results": true, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03330847" }, { "nct_id": "NCT00582478", "title": "Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 650, "start_date": "2001-10", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00582478" }, { "nct_id": "NCT00096343", "title": "Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 31, "start_date": "2002-10", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2018-12-04", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096343" }, { "nct_id": "NCT05954143", "title": "Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "BDC-1001", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bolt Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2023-11-30", "completion_date": "2024-09-25", "has_results": true, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-10-27T09:45:20.361Z", "location_count": 3, "location_summary": "Irvine, California • New York, New York • Arlington, Virginia", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Arlington", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05954143" } ] }